Ra pharmaceuticals, inc. (RARX)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15
Revenue

-

0

-

-

-

-

-

-

-

-

-

-

4,928

6,024

0

0

0

Operating expenses:
Research and development

82,642

71,797

61,928

56,319

54,449

51,737

51,492

49,651

45,251

41,993

35,942

31,983

27,928

22,568

0

0

0

General and administrative

27,337

19,514

17,046

15,934

14,439

13,314

12,094

10,621

9,778

8,707

7,465

6,202

5,024

3,957

0

0

0

Total operating expenses

109,979

91,311

78,974

72,253

68,888

65,051

63,586

60,272

55,029

50,700

43,407

38,185

32,952

26,525

0

0

0

Loss from operations

-106,979

-85,811

-76,474

-69,753

-66,388

-65,051

-63,586

-60,272

-55,029

-50,700

-43,407

-35,141

-28,024

-20,501

0

0

0

Other income (expense):
Interest expense with related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss on debt extinguishment with related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Other expense, net

-23

2,222

1,356

786

-38

498

262

31

-74

387

255

-154

-967

-791

0

0

0

Total other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss

-102,688

-82,106

-73,635

-67,484

-64,943

-63,889

-62,660

-59,577

-54,439

-50,186

-43,025

-35,168

-28,864

-21,908

0

0

0

Gain on extinguishment of redeemable convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss per share - basic and diluted (in dollars per share)

-0.79

-0.55

-0.52

-0.45

-0.45

-0.51

-0.49

-0.61

-0.67

-0.68

-0.56

-0.50

25.56

-14.22

-8.90

-9.42

-4.57

Weighted average number of common shares outstanding - basic and diluted (in shares)

47,218

45,766

42,294

42,174

34,270

32,349

32,307

27,242

22,626

22,614

22,575

22,549

14,892

571

540

537

494